Validation of Novel Target Combination for Bispecific ADCs by Increasing Tumor Selectivity & Reducing Off-Target Toxicity

• Outlining target combination rationale for bispecific ADC design
• Assessing preclinical safety and efficacy of bispecific ADCs compared vs monospecific ADCs
• Important points to prepare for IND applications and clinical trials of bispecific ADCs